Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven D Rhodes

Showing results (11-20 of 49) with videos related to

Pageof 5
Sort By:
Hypertension (Dallas, Tex. : 1979)|May 28, 2008
Endothelial function and aminothiol biomarkers of oxidative stress in healthy adultsSalman Ashfaq, Jerome L Abramson, Dean P Jones, et al.
Clinical Trials (London, England)|October 31, 2023
Recommendations for the collection and annotation of biosamples for analysis of biomarkers in neurofibromatosis and schwannomatosis clinical trialsR Taylor Sundby, Steven D Rhodes, Edina Komlodi-Pasztor, et al.
The Journal of Investigative Dermatology|May 28, 2023
RAS Signaling Gone Awry in the Skin: The Complex Role of RAS in Cutaneous Neurofibroma Pathogenesis, Emerging Biological InsightsSteven D Rhodes, Frank McCormick, Ross L Cagan, et al.
Frontiers in Oncology|June 10, 2024
Neratinib, a pan ERBB/HER inhibitor, restores sensitivity of <i>PTEN</i>-null, <i>BRAFV600E</i> melanoma to BRAF/MEK inhibitionEvan DuBose, Samantha M Bevill, Dana K Mitchell, et al.
Biorxiv : the Preprint Server for Biology|May 15, 2024
A novel induced pluripotent stem cell model of Schwann cell differentiation reveals <i>NF2</i> - related gene regulatory networks of the extracellular matrixOlivia Lazaro, Sihong Li, William Carter, et al.
The Journal of Investigative Dermatology|June 9, 2023
Target Product Profile for Cutaneous Neurofibromas: Clinical Trials to Prevent, Arrest, or Regress Cutaneous NeurofibromasIna Ly, Carlos G Romo, Sally Gottesman, et al.
Molecular Oncology|May 31, 2021
SIK2 kinase synthetic lethality is driven by spindle assembly defects in FANCA-deficient cellsKa-Kui Chan, Zahi Abdul-Sater, Aditya Sheth, et al.
Plos One|November 13, 2012
c-Fms signaling mediates neurofibromatosis Type-1 osteoclast gain-in-functionsYongzheng He, Steven D Rhodes, Shi Chen, et al.
Bone|March 29, 2011
Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine modelWei Zhang, Steven D Rhodes, Liming Zhao, et al.
Plos One|March 19, 2015
Dystrophic spinal deformities in a neurofibromatosis type 1 murine modelSteven D Rhodes, Wei Zhang, Dalong Yang, et al.
Pageof 5

Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
Hypertension (Dallas, Tex. : 1979)|May 28, 2008
Endothelial function and aminothiol biomarkers of oxidative stress in healthy adultsSalman Ashfaq, Jerome L Abramson, Dean P Jones, et al.
Clinical Trials (London, England)|October 31, 2023
Recommendations for the collection and annotation of biosamples for analysis of biomarkers in neurofibromatosis and schwannomatosis clinical trialsR Taylor Sundby, Steven D Rhodes, Edina Komlodi-Pasztor, et al.
The Journal of Investigative Dermatology|May 28, 2023
RAS Signaling Gone Awry in the Skin: The Complex Role of RAS in Cutaneous Neurofibroma Pathogenesis, Emerging Biological InsightsSteven D Rhodes, Frank McCormick, Ross L Cagan, et al.
Frontiers in Oncology|June 10, 2024
Neratinib, a pan ERBB/HER inhibitor, restores sensitivity of <i>PTEN</i>-null, <i>BRAFV600E</i> melanoma to BRAF/MEK inhibitionEvan DuBose, Samantha M Bevill, Dana K Mitchell, et al.
Biorxiv : the Preprint Server for Biology|May 15, 2024
A novel induced pluripotent stem cell model of Schwann cell differentiation reveals <i>NF2</i> - related gene regulatory networks of the extracellular matrixOlivia Lazaro, Sihong Li, William Carter, et al.
The Journal of Investigative Dermatology|June 9, 2023
Target Product Profile for Cutaneous Neurofibromas: Clinical Trials to Prevent, Arrest, or Regress Cutaneous NeurofibromasIna Ly, Carlos G Romo, Sally Gottesman, et al.
Molecular Oncology|May 31, 2021
SIK2 kinase synthetic lethality is driven by spindle assembly defects in FANCA-deficient cellsKa-Kui Chan, Zahi Abdul-Sater, Aditya Sheth, et al.
Plos One|November 13, 2012
c-Fms signaling mediates neurofibromatosis Type-1 osteoclast gain-in-functionsYongzheng He, Steven D Rhodes, Shi Chen, et al.
Bone|March 29, 2011
Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine modelWei Zhang, Steven D Rhodes, Liming Zhao, et al.
Plos One|March 19, 2015
Dystrophic spinal deformities in a neurofibromatosis type 1 murine modelSteven D Rhodes, Wei Zhang, Dalong Yang, et al.
Pageof 5